BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28501118)

  • 1. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.
    Gratian L; Pura J; Dinan M; Roman S; Reed S; Sosa JA
    Ann Surg Oncol; 2014 Oct; 21(11):3515-21. PubMed ID: 24841347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
    Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
    HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors.
    Raoof M; Jutric Z; Melstrom LG; Lee B; Li D; Warner SG; Fong Y; Singh G
    Surgery; 2019 Apr; 165(4):760-766. PubMed ID: 30447803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
    Kuo EJ; Salem RR
    Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
    Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
    Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
    Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.